Ranitidine: patients taking certain batches should “immediately discontinue use,” says FDABMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l7053 (Published 19 December 2019) Cite this as: BMJ 2019;367:l7053
- Elisabeth Mahase
- The BMJ
Patients who have ranitidine tablets from certain batches, identified through the US’s National Drug Code, should “immediately discontinue use and consult with their physician or healthcare provider about treatment options,” says an alert from Glenmark Pharmaceuticals.1
The alert, published on the US Food and Drug Administration website, said that the company had announced a voluntary recall of all unexpired lots of ranitidine tablets (150 mg and 300 mg), including from patients.
The recalled 150 mg batches are: NDC 684620-248-60; 684620-248-01; and 684620-248-05 (expiry date range December 2019 to May 2022). The recalled 300 mg batches are: 684620-249-30; 684620-249-01; and 684620-249-20 …